This medicines update is provided by the Veterinary Medicines Directorate (VMD) and lists new active substance, new marketing authorisations and changes to authorisations most relevant to vets.
Changes to authorisations most relevant to vets
The changes to authorisations most relevant to vets can be found below. Each product listed, along with the authorisation holder, distribution category and details of which Summary of Product Characteristics sections have been revised/changed.
All entries can be found on the VMD’s Product Information Database at www.gov.uk/check-animal-medicine-licensed.
Changes to the SPC, labels and leaflets may change how the medicines should be used. There may be a delay between these changes being authorised to implementation on product literature. Unless you have been advised otherwise, the labelling instructions on the pack which is dispensed should be followed.
Zylexis for horses
Zoetis UK Limited, Authorised for UK, POM-V
Section 4.6: Hyperthermia associated with general malaise and musculoskeletal signs (stiffness, abnormal posture, tense muscle) have been observed very rarely in spontaneous reports.
Hypersensitivity reactions (i.e. circulatory shock, tachycardia, abdominal pain, convulsion) may occur very rarely. Such reactions may evolve to a more severe condition (anaphylaxis), which may be life-threatening. No local or systemic reactions are expected after the administration of the recommended dose of Zylexis for horses.
For This medicines update is provided by the Veterinary Medicines Directorate (VMD) and lists new active substance, new marketing authorisations and changes to authorisations most relevant to vets.
For more information, contact the VMD at email@example.com